⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure 4 from Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer

Kavya Ramkumar Azusa Tanimoto Carminia M. Della Corte C. Allison Stewart Qi Wang Li Shen Robert J. Cardnell Jing Wang Urszula M. Polanska Courtney L. Andersen Jamal Saeh J. Elizabeth Pease Jon Travers Giulia Fabbri Carl M. Gay Jelena Urosevic Lauren A. Byers

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 4 shows the combination of AZD2811NP with venetoclax is well tolerated in mice and less efficacious in SCLC models with low BCL2 expression.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ramkumar et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db643587523827 https://doi.org/10.1158/1078-0432.27032236

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 4 from Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer2024
2Supplementary Figure 1 from Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer2024
3Supplementary Figure 1 from Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer2024
4Supplementary Figure 3 from Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer2024
5Supplementary Figure 3 from Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer2024